Lung Cancer:: Prevention, Management, and Emerging Therapies (Current Clinical Oncology)

This comprehensive resource provides authoritative knowledge of the most up-to-date prevention and treatment strategies for thoracic malignancies. Established and investigational therapies are placed in the context of tumor biology for a full understanding of the pharmacogenetics, etiology, and changing epidemiology of lung cancer. Expert clinicians detail the function of predictive and prognostic factors in the utilization of chemo-radiotherapy, adjuvant and neoadjuvant treatment, and targeted agents. The promises and potential pitfalls of investigational strategies are evaluated with exceptional insight and clarity, with unique attention paid to the mechanisms of drug resistance and targets for lung cancer treatment and prevention. Lung Cancer: Prevention, Management, and Emerging Therapies engages the entire spectrum of therapeutic modalities with focus on systemic approaches. Disease coverage includes newly diagnosed and recurrent non-small cell lung cancer, small cell carcinoma, and mesothelioma. Critical examination of the impact, methodology, and design of clinical trials is presented along with new paradigms for personalized approaches and individual risk assessment. Front Matter....Pages i-xvi Molecular Pathology of Lung Cancer....Pages 1-25 Tumor Microenvironment....Pages 27-69 Racial and Ethnic Diversity in Lung Cancer....Pages 71-85 Pharmacogenetics of Lung Cancer....Pages 87-106 Lung Cancer Prevention....Pages 107-138 Adjuvant and Neoadjuvant Therapy of NSCLC....Pages 139-159 Chemoradiotherapy for Inoperable Non-small Cell Lung Cancer....Pages 161-175 Management of Advanced Non-small Cell Lung Cancer: Front Line Treatment....Pages 177-194 Chemotherapy in Previously Treated Patients with Non-small Cell Lung Cancer....Pages 195-204 Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer....Pages 205-226 Angiogenesis Inhibitors in Lung Cancer....Pages 227-252 Other Molecular Targeted Agents in Non-small Cell Lung Cancer....Pages 253-278 Vaccine Therapy for Lung Cancer....Pages 279-303 Gene-Based Therapies for Lung Cancer....Pages 305-330 Lung Cancer Resistance to Chemotherapy....Pages 331-393 Small Cell Carcinoma of the Lung....Pages 395-434 Mesothelioma....Pages 435-465 Advances in Oncology Clinical Research: Statistical and Study Design Methodologies....Pages 467-481 Palliative Care for Patients with Lung Cancer....Pages 483-502 The Future of Lung Cancer....Pages 503-514 Back Matter....Pages 515-538 Defining the Lung Cancer Problem 1 Lung cancer is the leading cause of cancer death in the world. It kills almost as many Americans as cancers of the breast, prostate, colon, rectum, pancreas, and 2 kidney combined, and accounts for 28.6% of all US cancer deaths. With an increase in the 5-year relative survival rate from 13% to only 16% in the more than 2 30 years from 1974 to the present, it will take us another 840 years to eradicate lung cancer deaths if we do not improve the current rate of progress. As discussed in this text, lung cancer prevention has received substantial att- tion. The decrease in smoking in recent decades has helped, but smoking is not the only problem. Lung cancer in people who have never smoked is currently the 5th 3 leading cause of cancer death in the United States. Several factors contribute to the lethality of lung cancer, including the rapidity of tumor growth, advanced stage at diagnosis (due to nonspecificity of early sy- toms and the uncertain efficacy of screening), early development of metastases, and resistance to therapy. Several chapters in this book discuss new molecular targets that may be potentially exploitable in the future, as well as discussing our track record to date in exploiting them. Annotation This comprehensive resource provides authoritative knowledge of the most up-to-date prevention and treatment strategies for thoracic malignancies. Established and investigational therapies are placed in the context of tumor biology for a full understanding of the pharmacogenetics, etiology, and changing epidemiology of lung cancer. Expert clinicians detail the function of predictive and prognostic factors in the utilization of chemo-radiotherapy, adjuvant and neoadjuvant treatment, and targeted agents. The promises and potential pitfalls of investigational strategies are evaluated with exceptional insight and clarity, with unique attention paid to the mechanisms of drug resistance and targets for lung cancer treatment and prevention.Lung Cancer: Prevention, Management, and Emerging Therapies engages the entire spectrum of therapeutic modalities with focus on systemic approaches. Disease coverage includes newly diagnosed and recurrent non-small cell lung cancer, small cell carcinoma, and mesothelioma. Critical examination of the impact, methodology, and design of clinical trials is presented along with new paradigms for personalized approaches and individual risk assessment